ARA 290 | 10 mg

What is ARA 290?

ARA 290, also known as Cibinetide, is a synthetic peptide derived from erythropoietin (EPO) that selectively targets the heteromeric innate repair receptor (IRR). Unlike conventional EPO, this compound does not stimulate red blood cell production, but focuses exclusively on signaling pathways associated with tissue protection and repair. Its molecular design allows it to activate cytoprotective mechanisms without the typical erythropoietic effects of EPO.

Mechanism of action of ARA 290

El mecanismo de acción de ARA 290 se basa en su interacción con el receptor heteromérico compuesto por el receptor de EPO y el receptor beta común (CD131). Esta unión selectiva desencadena cascadas de señalización intracelular que activan vías antiinflamatorias, antiapoptóticas y neuroprotectoras. Al actuar sobre este receptor específico, el péptido promueve la supervivencia celular y la reparación de tejidos dañados sin estimular la eritropoyesis.

A nivel celular, este compuesto modula la respuesta inflamatoria mediante la regulación de citoquinas proinflamatorias, activa las vías de señalización JAK2/STAT5 y PI3K/Akt, y promueve la expresión de genes asociados con la protección neuronal. Estos mecanismos confieren al péptido un perfil farmacológico único orientado a la reparación tisular.

ARA 290 investigated benefits

Scientific research has identified multiple potential effects associated with the administration of this peptide:

• Neuroprotection: Preclinical and clinical studies have shown that this compound exerts protective effects on the nervous system, promoting neuronal survival and nerve fiber regeneration in models of neuropathy.
• Inflammatory modulation: Research indicates that the peptide significantly reduces markers of systemic inflammation by acting on proinflammatory cytokine signaling pathways such as TNF-α and IL-6.
• Metabolic protection: Studies have explored the potential of this compound in the protection of pancreatic beta cells and the modulation of insulin sensitivity in research models.
• Tissue repair: As an activator of the innate repair receptor, this peptide has shown the ability to accelerate the recovery of damaged tissues in various experimental models.

Research applications

ARA 290 ha sido estudiado extensamente en el contexto de la neurociencia y la medicina regenerativa. Las principales líneas de investigación incluyen el estudio de la neuropatía diabética, la sarcoidosis, la protección de órganos durante trasplantes y la modulación de la respuesta inflamatoria crónica. Su perfil de seguridad favorable en ensayos clínicos ha posicionado a este péptido como un compuesto prometedor para futuras investigaciones terapéuticas.

Investigaciones publicadas en revistas como PubMed have documented the effects of this compound in multiple experimental models, confirming its cytoprotective activity and its potential in translational medicine.

Scientific context

Since its development by Araim Pharmaceuticals, ARA 290 has been the subject of multiple Phase I and II clinical trials. Studies have shown that this peptide is well tolerated and has a favorable safety profile. Its unique mechanism of action, acting on the innate repair receptor without affecting erythropoiesis, distinguishes it from other EPO-derived compounds and makes it a valuable tool for biomedical research.

Why choose ARA 290 from Peptilife Colombia?

At Peptilife Colombia we offer ARA 290 10 mg with purity verified by HPLC ≥98%. Our product is lyophilized to ensure maximum stability and shelf life. All our peptides meet the highest quality standards for scientific research.

Product specifications

• Name: ARA 290 (Cibinetide)
• Presentation: 10 mg per vial
• Purity: ≥98% verified by HPLC
• Shape: Lyophilized powder
• Storage: Store at -20°C. Once reconstituted, refrigerate at 2-8°C.

Product intended for research purposes only.